Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors

Table 2 General and clinicopathological characteristics of patients (n = 120)

Groups		Experimental group		Control group		P value
Groups		Frequency	Percentage (%)	Frequency	Percentage (%)	P value
Gender	Male	49	81.67	44	73.33	0.274^a
Gender	Female	11	18.33	16	26.67	0.274^a
Diagnosis	Colon cancer metastases	6	10	6	10	0.066^a
	Postoperative colon cancer	8	13.33	11	18.33
	Gastric cancer metastases	4	6.67	3	5
	Postoperative gastric cancer	32	53.33	17	28.33
	Rectal cancer metastases	3	5	7	11.67
	Postoperative rectal cancer	7	11.67	16	26.67
First-line therapy	No	44	73.33	43	71.67	0.838^a
First-line therapy	Yes	16	26.67	17	28.33	0.838^a
Smoking	No	38	63.33	39	65.00	0.849^a
Smoking	Yes	22	36.67	21	35.00	0.849^a
Drinking	No	46	76.67	40	66.67	0.224^a
Drinking	Yes	14	23.33	20	33.33	0.224^a
Diabetes	No	51	85.00	54	90.00	0.408^a
Diabetes	Yes	9	15.00	6	10.00	0.408^a
Chemotherapy regimen	FOLFOX4	13	21.67	20	33.33	0.152^a
Chemotherapy regimen	XELOX	47	78.33	40	66.67	0.152^a
Clinical evaluation	CR	1	1.67	1	1.67	nd^b
	PD	2	3.33	3	5.00
	PR	7	11.67	3	5.00
	SD	6	10.00	10	16.67
	Assistance	44	73.33	43	71.67

^aComparisons performed using χ² test; ^bThe sample number is small and comparisons are not done. CR, Complete Response;nd, not done; PD,Progressive Disease; PR, Partial Response;SD,Stable Disease.

ISSN: 1477-7819